ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Coronary Disease - Other

June 15, 2021
Fascinating confirmation of null hypotheses including bleeding complications and survival in a Pennsylvanian cohort study, despite the easily predictable previous PCI, hock, and IABP prevalence in the emergency group. The statistical model is elaborate and complex. Perhaps a randomized trial could now be justified!
May 27, 2021
This month's update on the economical and general aspects of the ROOBY-FS trial. The conclusion (on no impact of de novo post-CABG AF on the incidence of stroke nor the 5 year expenditure ) challenges many hitherto perceptions on this frequent compication of coronary surgery.
February 21, 2021
An editorial that may herald the decrease in aspirinization and the rise of ticagrelor monotherapy in Percutaneous stenting of coronary arteries.
December 10, 2020
An ad hoc interim analysis pursuant to previous publications raising concerns on Paclitaxel DCS in chronic critical and not-critical lower limb ischaemia. The short manuscript requires careful reading to form an individual opinion beyond the relatively simple arithmetics: slightly more deaths in the intervention group.
October 26, 2020
Within the limitations of a meta-analysis, a useful work advancing that PCI may have a hitherto masked or hidden mortality
October 12, 2020
An analysis, from the cardiology viewpoint, of the MI nomenclature issues around the external validity of the EXCEL trial that undermined the EACTS support of the relevant 2018 guidelines
October 4, 2020
The authors are concerned about the 'deaths at home' having the greatest contribution to the excess of acute cardiovascular deaths in that period of the recent epidemic, AND LOCKDOWN in England and Wales.
October 1, 2020
Death from cardiovascular causes, stroke, or hospitalization with worsening of heart failure or acute coronary syndrome was reduced (P=0.005) by early pharmacogical or inteventional ablation for fast response-atrial fibrillation in a small German RCT. 
September 15, 2020
An open-access large metanalysis on the utility and risks of antiplatelets after PCI. Of note, mortality was not a primary endpoint. The message is that long dual antiplatelet use is an exchange between avoidance of myocardial events and serious bleeding. The novel oral anticoagulants may enter the arena soon..
April 3, 2020
In the ISCHEMIA Trial, 5179 patients with moderate or severe myocardial ischemia were randomized equally into two groups based on initial management strategy: initial invasive strategy (angiography and revascularization when feasible) and medical therapy, or initial conservative strategy (medical therapy alone and angiography if medical therapy faile

Pages